Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMO | Q99835 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733366 | 1.00 | EHMT2 (0.42) | EHMT2BRD4ALDH1A1TDP1KDM4E | |
| SCHEMBL21584135 | 0.86 | TDP1 (0.50) | ALDH1A1TDP1KDM4EPOLBAPEX1 | |
| SCHEMBL5735391 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TDP1GRM2 | |
| SCHEMBL5735392 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TDP1GRM2 | |
| SCHEMBL23420392 | 0.81 | BRD4 (0.39) | EHMT2BRD4ALDH1A1TDP1KDM4E | |
| SCHEMBL22222461 | 0.81 | EHMT2 (0.47) | EHMT2ALDH1A1TDP1GRM2MEN1 | |
| SCHEMBL20794245 | 0.81 | EHMT2 (0.47) | EHMT2ALDH1A1TDP1GRM2MEN1 | |
| SCHEMBL31372659 | 0.79 | EHMT2 (0.44) | EHMT2BRD4ALDH1A1TDP1KDM4E | |
| SCHEMBL21584139 | 0.79 | EHMT2 (0.42) | EHMT2BRD4ALDH1A1TDP1GRM2 | |
| SCHEMBL23439941 | 0.79 | EHMT2 (0.42) | EHMT2BRD4ALDH1A1TDP1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4067363-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-10-05 | — | — | EP | disclosed |
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| EP-3805231-A1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-0933379-B1 | NOVEL PEPTIDE DERIVATIVES HAVING THIAZOLYL-ALANINE RESIDUE | SHIONOGI & CO (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-6319902-B1 | TO ACTIVATE THE CENTRAL NERVOUS SYSTEM, SUCH AS, FOR EXAMPLE, SUSTAINED ACETYLCHOLINE RELEASING ACTION, ANTI-RESERPINE ACTION AND LOCOMOTOR INCREMENT | SHIONOGI & CO., LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-0933379-A1 | NOVEL PEPTIDE DERIVATIVES HAVING THIAZOLYL-ALANINE RESIDUE | SHIONOGI & CO., LTD. (JP) | 1999-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221822-A1 | TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF | PIK3CA, PIK3CD, PIK3CB | EHMT2 3962/4885BRD4 1462/4885ALDH1A1 3676/4885 |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | AKT2, AKT3, PIK3R5 | EHMT2 4609/4885BRD4 3163/4885ALDH1A1 3960/4885 |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | OGDH, ME1, GCDH | EHMT2 4455/4885BRD4 4420/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.